JP2017105862A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017105862A5 JP2017105862A5 JP2017061095A JP2017061095A JP2017105862A5 JP 2017105862 A5 JP2017105862 A5 JP 2017105862A5 JP 2017061095 A JP2017061095 A JP 2017061095A JP 2017061095 A JP2017061095 A JP 2017061095A JP 2017105862 A5 JP2017105862 A5 JP 2017105862A5
- Authority
- JP
- Japan
- Prior art keywords
- vertebral fracture
- weeks
- inhibitor
- period exceeding
- administered over
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010041569 spinal fracture Diseases 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 4
- 108090000445 Parathyroid hormone Proteins 0.000 claims 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims 2
- 239000000199 parathyroid hormone Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010068975 Bone atrophy Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000037182 bone density Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009208039 | 2009-09-09 | ||
| JP2009208039 | 2009-09-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016219323A Division JP2017061511A (ja) | 2009-09-09 | 2016-11-10 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017105862A JP2017105862A (ja) | 2017-06-15 |
| JP2017105862A5 true JP2017105862A5 (enExample) | 2017-07-27 |
Family
ID=43732444
Family Applications (13)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530844A Pending JPWO2011030774A1 (ja) | 2009-09-09 | 2010-09-08 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2015105265A Active JP6150846B2 (ja) | 2009-09-09 | 2015-05-25 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2015105266A Active JP6198346B2 (ja) | 2009-09-09 | 2015-05-25 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2016082589A Active JP6043008B2 (ja) | 2009-09-09 | 2016-04-18 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2016219323A Pending JP2017061511A (ja) | 2009-09-09 | 2016-11-10 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2017061093A Active JP6301524B2 (ja) | 2009-09-09 | 2017-03-27 | 骨粗鬆症治療剤ないし予防剤 |
| JP2017061094A Withdrawn JP2017105861A (ja) | 2009-09-09 | 2017-03-27 | 骨粗鬆症治療剤ないし予防剤 |
| JP2017061091A Active JP6275900B2 (ja) | 2009-09-09 | 2017-03-27 | 骨粗鬆症治療剤ないし予防剤 |
| JP2017061096A Pending JP2017105863A (ja) | 2009-09-09 | 2017-03-27 | 骨粗鬆症治療剤ないし予防剤 |
| JP2017061095A Withdrawn JP2017105862A (ja) | 2009-09-09 | 2017-03-27 | 椎体骨折抑制剤 |
| JP2017061092A Active JP6274634B2 (ja) | 2009-09-09 | 2017-03-27 | 骨粗鬆症治療剤ないし予防剤 |
| JP2017221570A Active JP6522715B2 (ja) | 2009-09-09 | 2017-11-17 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2018215152A Pending JP2019023234A (ja) | 2009-09-09 | 2018-11-16 | 骨粗鬆症治療剤ないし予防剤 |
Family Applications Before (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530844A Pending JPWO2011030774A1 (ja) | 2009-09-09 | 2010-09-08 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2015105265A Active JP6150846B2 (ja) | 2009-09-09 | 2015-05-25 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2015105266A Active JP6198346B2 (ja) | 2009-09-09 | 2015-05-25 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2016082589A Active JP6043008B2 (ja) | 2009-09-09 | 2016-04-18 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2016219323A Pending JP2017061511A (ja) | 2009-09-09 | 2016-11-10 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2017061093A Active JP6301524B2 (ja) | 2009-09-09 | 2017-03-27 | 骨粗鬆症治療剤ないし予防剤 |
| JP2017061094A Withdrawn JP2017105861A (ja) | 2009-09-09 | 2017-03-27 | 骨粗鬆症治療剤ないし予防剤 |
| JP2017061091A Active JP6275900B2 (ja) | 2009-09-09 | 2017-03-27 | 骨粗鬆症治療剤ないし予防剤 |
| JP2017061096A Pending JP2017105863A (ja) | 2009-09-09 | 2017-03-27 | 骨粗鬆症治療剤ないし予防剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017061092A Active JP6274634B2 (ja) | 2009-09-09 | 2017-03-27 | 骨粗鬆症治療剤ないし予防剤 |
| JP2017221570A Active JP6522715B2 (ja) | 2009-09-09 | 2017-11-17 | １回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤 |
| JP2018215152A Pending JP2019023234A (ja) | 2009-09-09 | 2018-11-16 | 骨粗鬆症治療剤ないし予防剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20120252729A1 (enExample) |
| EP (3) | EP2476429B1 (enExample) |
| JP (13) | JPWO2011030774A1 (enExample) |
| KR (8) | KR20170089018A (enExample) |
| CN (2) | CN103893746A (enExample) |
| AU (1) | AU2010293488B2 (enExample) |
| BR (1) | BR112012003511A2 (enExample) |
| CA (1) | CA2772656A1 (enExample) |
| ES (3) | ES2662018T3 (enExample) |
| IL (1) | IL217854A (enExample) |
| IN (1) | IN2012DN00857A (enExample) |
| MX (1) | MX335951B (enExample) |
| NZ (2) | NZ598370A (enExample) |
| RU (1) | RU2564894C2 (enExample) |
| WO (1) | WO2011030774A1 (enExample) |
| ZA (1) | ZA201201720B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2502632B1 (en) * | 2009-11-18 | 2016-12-28 | Asahi Kasei Pharma Corporation | Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis |
| JP6235219B2 (ja) * | 2013-03-21 | 2017-11-22 | 旭化成ファーマ株式会社 | 脊椎椎体間固定術後の骨癒合促進剤 |
| US10394953B2 (en) | 2015-07-17 | 2019-08-27 | Facebook, Inc. | Meme detection in digital chatter analysis |
| JP2020506926A (ja) * | 2017-02-01 | 2020-03-05 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 副甲状腺ホルモンと変性椎間板疾患の再生 |
| WO2019059303A1 (ja) * | 2017-09-22 | 2019-03-28 | 旭化成ファーマ株式会社 | 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物 |
| JP2019060866A (ja) * | 2017-09-22 | 2019-04-18 | 旭化成ファーマ株式会社 | 液状医薬組成物の体内動態を予測する方法 |
| US20200289621A1 (en) * | 2017-09-22 | 2020-09-17 | Asahi Kasei Pharma Corporation | Teriparatide-containing liquid pharmaceutical composition having excellent stability |
| CN111447943A (zh) | 2018-10-29 | 2020-07-24 | 旭化成制药株式会社 | 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法 |
| KR102920552B1 (ko) * | 2024-01-03 | 2026-01-30 | 김도영 | 나노입자경의 탄산칼슘과 탄산마그네슘 제조방법 및 그 방법으로 제조된 골다공증 예방치료제 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2505812B2 (ja) | 1987-07-10 | 1996-06-12 | 旭化成工業株式会社 | ｈ―ＰＴＨ（１―３４）凍結乾燥組成物 |
| JP2662842B2 (ja) | 1991-12-09 | 1997-10-15 | 旭化成工業株式会社 | パラサイロイドホルモンの安定化組成物 |
| JPH0873376A (ja) | 1994-09-07 | 1996-03-19 | Asahi Chem Ind Co Ltd | 骨粗鬆症治療薬 |
| SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| MY120063A (en) * | 1997-12-09 | 2005-08-30 | Lilly Co Eli | Stabilized teriparatide solutions |
| AR033639A1 (es) | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
| US6756480B2 (en) * | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| BR0112381A (pt) | 2000-06-30 | 2003-05-06 | Suntory Ltd | Componente farmacêutico com base em hormÈnio da paratireóide humana e uma composição farmacêutica para administração intranasal compreendendo o componente |
| JP5042419B2 (ja) * | 2001-08-15 | 2012-10-03 | 旭化成ファーマ株式会社 | 骨形成促進剤および骨形成促進組成物 |
| JP4931306B2 (ja) | 2001-09-27 | 2012-05-16 | 旭化成ファーマ株式会社 | 骨形成を安全に促進させる医薬複合剤 |
| JP2007525472A (ja) * | 2003-07-04 | 2007-09-06 | ニコメド ダンマーク エイピーエス | 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物 |
| JPWO2005102381A1 (ja) * | 2004-04-26 | 2008-03-06 | 小野薬品工業株式会社 | カテプシンｋ阻害薬およびｐｔｈ類を併用することを特徴とする骨密度増加剤 |
| US7244709B2 (en) * | 2004-05-10 | 2007-07-17 | Nastech Pharamecutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| US7799754B2 (en) * | 2004-10-14 | 2010-09-21 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating bone |
| JP2006241098A (ja) * | 2005-03-04 | 2006-09-14 | Univ Kurume | 骨量減少症の予防または治療薬 |
| DE102006043846A1 (de) * | 2006-03-14 | 2007-09-20 | Claudia Zours | Wirbelsäulenorthesen |
| WO2007106597A2 (en) * | 2006-03-15 | 2007-09-20 | Alza Corporation | Method for the transdermal delivery of parathyroid hormone agents for treating osteopenia |
| CN101274961A (zh) * | 2006-03-30 | 2008-10-01 | 天津医科大学 | 重组人甲状旁腺素相关蛋白 |
| CN101125201A (zh) * | 2006-08-17 | 2008-02-20 | 石家庄欧意药业有限公司 | 治疗骨质疏松症或防治由于骨质疏松而导致的骨折的药物组合物及其应用 |
| CN101307105B (zh) * | 2008-04-28 | 2012-08-29 | 中国药科大学 | 一种能串联表达和同步酸水解释放的人甲状旁腺素1-34肽类似物及其制备方法和应用 |
-
2010
- 2010-09-08 ES ES13181713.2T patent/ES2662018T3/es active Active
- 2010-09-08 EP EP10815369.3A patent/EP2476429B1/en active Active
- 2010-09-08 MX MX2012002681A patent/MX335951B/es unknown
- 2010-09-08 IN IN857DEN2012 patent/IN2012DN00857A/en unknown
- 2010-09-08 AU AU2010293488A patent/AU2010293488B2/en active Active
- 2010-09-08 KR KR1020177019824A patent/KR20170089018A/ko not_active Ceased
- 2010-09-08 KR KR1020177019823A patent/KR20170089017A/ko not_active Ceased
- 2010-09-08 KR KR1020127005972A patent/KR20120067336A/ko not_active Ceased
- 2010-09-08 EP EP13181715.7A patent/EP2682125B1/en active Active
- 2010-09-08 JP JP2011530844A patent/JPWO2011030774A1/ja active Pending
- 2010-09-08 ES ES10815369.3T patent/ES2663322T3/es active Active
- 2010-09-08 KR KR20157003153A patent/KR20150021590A/ko not_active Ceased
- 2010-09-08 WO PCT/JP2010/065379 patent/WO2011030774A1/ja not_active Ceased
- 2010-09-08 KR KR1020197023161A patent/KR20190095552A/ko not_active Ceased
- 2010-09-08 ES ES13181715T patent/ES2843649T3/es active Active
- 2010-09-08 US US13/395,000 patent/US20120252729A1/en not_active Abandoned
- 2010-09-08 CN CN201410092512.5A patent/CN103893746A/zh active Pending
- 2010-09-08 BR BR112012003511A patent/BR112012003511A2/pt not_active IP Right Cessation
- 2010-09-08 KR KR20147029471A patent/KR20140130754A/ko not_active Withdrawn
- 2010-09-08 NZ NZ598370A patent/NZ598370A/en unknown
- 2010-09-08 EP EP13181713.2A patent/EP2682124B1/en active Active
- 2010-09-08 RU RU2012108635/15A patent/RU2564894C2/ru active
- 2010-09-08 CA CA2772656A patent/CA2772656A1/en not_active Abandoned
- 2010-09-08 KR KR1020207027785A patent/KR102335703B1/ko active Active
- 2010-09-08 CN CN201080034494.5A patent/CN102470164B/zh active Active
- 2010-09-08 KR KR1020217009475A patent/KR102424644B1/ko active Active
- 2010-09-08 NZ NZ617397A patent/NZ617397A/en unknown
-
2012
- 2012-01-31 IL IL217854A patent/IL217854A/en active IP Right Grant
- 2012-03-08 ZA ZA2012/01720A patent/ZA201201720B/en unknown
-
2014
- 2014-03-05 US US14/197,607 patent/US20140249084A1/en not_active Abandoned
- 2014-07-14 US US14/330,124 patent/US20140357560A1/en not_active Abandoned
-
2015
- 2015-05-25 JP JP2015105265A patent/JP6150846B2/ja active Active
- 2015-05-25 JP JP2015105266A patent/JP6198346B2/ja active Active
-
2016
- 2016-04-18 JP JP2016082589A patent/JP6043008B2/ja active Active
- 2016-11-10 JP JP2016219323A patent/JP2017061511A/ja active Pending
-
2017
- 2017-03-27 JP JP2017061093A patent/JP6301524B2/ja active Active
- 2017-03-27 JP JP2017061094A patent/JP2017105861A/ja not_active Withdrawn
- 2017-03-27 JP JP2017061091A patent/JP6275900B2/ja active Active
- 2017-03-27 JP JP2017061096A patent/JP2017105863A/ja active Pending
- 2017-03-27 JP JP2017061095A patent/JP2017105862A/ja not_active Withdrawn
- 2017-03-27 JP JP2017061092A patent/JP6274634B2/ja active Active
- 2017-11-17 JP JP2017221570A patent/JP6522715B2/ja active Active
-
2018
- 2018-11-16 JP JP2018215152A patent/JP2019023234A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017105861A5 (enExample) | ||
| JP2017105859A5 (enExample) | ||
| JP2020023574A5 (ja) | 近視予防、治療又は抑制用点眼剤、及び、小胞体ストレス抑制用点眼剤 | |
| JP2014240439A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2020073529A5 (enExample) | ||
| JP2014139220A5 (enExample) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| PH12017500479A1 (en) | Liquid inhalation formulation comprising prl554 | |
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| JP2016534142A5 (enExample) | ||
| EP3808367A3 (en) | Targeting aneurysm disease by modulating phagocytosis pathways | |
| JP2016510326A5 (enExample) | ||
| MX2020012336A (es) | Formulacion farmaceutica. | |
| JP2019535723A5 (enExample) | ||
| JP2016027060A5 (enExample) | ||
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| WO2016011297A3 (en) | Methods and related compositions for improved drug bioavailability and disease treatment | |
| JP2021503483A5 (enExample) | ||
| HK1203394A1 (en) | Ghrelin receptor agonists for the treatment of achlorhydria | |
| MX2017013950A (es) | Polvos de zolmitriptán para suministro pulmonar. | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
| RU2017111848A (ru) | Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи |